Who
David A. Scheinberg
Director
Company insider
Files Form 4 as: Director, SELLAS Life Sciences Group; Director, Progenics Pharmaceuticals.
In numbers
- Trades disclosed
- 98
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.6M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 24 Jan 2006
- Last trade
- 7 Jan 2026
- Last filed
- 9 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jan 2026filed 9 Jan 2026 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 22 Jan 2024filed 25 Jan 2024 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 22 Jan 2024filed 25 Jan 2024 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,500 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 31 Jan 2022filed 1 Feb 2022 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,125 at $0.00 | filing |
| 31 Jan 2022filed 1 Feb 2022 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —1,900 at $0.00 | filing |
| 4 Mar 2021filed 8 Mar 2021 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 12 Mar 2020filed 16 Mar 2020 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 11 Jul 2019filed 15 Jul 2019 | Progenics Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Jul 2019filed 3 Jul 2019 | Progenics Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 1 Jul 2019filed 3 Jul 2019 | Progenics Pharmaceuticals | SEC FORM 4 Code M | $53K10,000 at $5.33 | filing |
| 14 Mar 2019filed 18 Mar 2019 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 13 Jun 2018filed 14 Jun 2018 | Progenics Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Jun 2018filed 13 Jun 2018 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 13 Mar 2018filed 15 Mar 2018 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 29 Dec 2017filed 16 Mar 2018 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —9,107 | filing |
News
No headline names them, or the companies they trade most, lately.